Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

SXTP

60 Degrees Pharmaceuticals (SXTP)

60 Degrees Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SXTP
DateTimeSourceHeadlineSymbolCompany
31/01/202506:20GlobeNewswire Inc.60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
30/01/202500:00GlobeNewswire Inc.60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
29/01/202500:01GlobeNewswire Inc.60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic BabesiosisNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
09/01/202500:02GlobeNewswire Inc.60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) BabesiosisNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
24/12/202400:57GlobeNewswire Inc.Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and PreventionNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
12/12/202400:56GlobeNewswire Inc.60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s HospitalNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
15/11/202406:31GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Third Quarter 2024 ResultsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
03/10/202423:02GlobeNewswire Inc.60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. LaunchNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
06/09/202422:59GlobeNewswire Inc.60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
04/09/202422:00GlobeNewswire Inc.60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
29/08/202405:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
29/08/202404:48GlobeNewswire Inc.60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing RequirementsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
15/08/202405:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
15/08/202401:01GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Second Quarter 2024 ResultsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
15/08/202400:29Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
13/08/202402:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
12/08/202423:12GlobeNewswire Inc.60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb StudyNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
06/08/202423:26GlobeNewswire Inc.60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock SplitNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
03/08/202406:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
27/07/202406:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
27/07/202403:21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
25/07/202423:02GlobeNewswire Inc.60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade SupportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
25/07/202407:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
23/07/202401:23Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
19/07/202422:29GlobeNewswire Inc.60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis StudyNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
19/07/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
17/07/202407:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
13/07/202407:02Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
10/07/202405:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
09/07/202420:31GlobeNewswire Inc.60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior TreatmentNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SXTP